BETWEENDevelopment and Manufacturing Service Agreement • October 5th, 2006 • Trubion Pharmaceuticals, Inc • Pharmaceutical preparations
Genenta Science and AGC Biologics Enter Development and Manufacturing Service AgreementDevelopment and Manufacturing Service Agreement • February 7th, 2023
MILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs. AGC Biologics offers end-to-end global viral vector and cell therapy development, manufacturing and quality/regulatory services, supported by scientists with 30 years of knowledge and experience.
ContractDevelopment and Manufacturing Service Agreement • February 26th, 2017
MolMed and Rocket Pharma establish a collaboration agreement in the field of gene therapy for the treatment of Fanconi Anemia
